1[1]Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation, 1979, 59(3): 607～609. 被引量：1
2[3]Reusch JE, Regensteiner JG, Watson PA. Novel actions of thiazolidinediones on vascular function and exercise capacity. Am J Med, 2003, 8;115 Suppl 8A:69～74. 被引量：1
3[6]Starry H C,Chander A B,Robert E, et al. A definition of advanced types of atheroscleotic lesions and A histological classification of atheroscleosis: A report from the committee on vascular lesions of the council on atherosclerosis. American Heart Association. Circulation, 1995, 92: 1355～1374. 被引量：1
5[8]Monroe VS, Kereasky RA, Rivera E, et al. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. J Am Coll Cardiol, 2003, 19;41(4 Suppl S): 23～30. 被引量：1
6[9]Attebring MF, Hartford M, Hjalmarson A, et al. Smoking habits and predictors of continued smoking in patients with acute coronary syndromes. J Adv Nurs, 2004, 46 (6): 614 ～623. 被引量：1
7[10]Goodacre SW, Angelini K, Arnold J, et al. Clinical predictors of acute coronary syndromes in pations with undifferentiated chest pain. QJM, 2003, 96(12):893～898. 被引量：1
8[11]Magadle R, Weiner P, Beckermen M, et al. C - reactive protein as a marker for active coronary disease in patients with chest pain in the emergency room. Clin Cardiol,2002, 25(10):456～460. 被引量：1
